Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis (EAP)

Expanded Access for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression

This program is to provide expanded access to aztreonam lysine for inhalation (AZLI) prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.

Study Overview

• Status: Approved for marketing
• Conditions: Cystic Fibrosis; Pseudomonas Aeruginosa
• Intervention / Treatment: Drug: Aztreonam lysine

• Study Type: Expanded Access

Contacts and Locations

Study Locations

• Canada
  • Alberta
    • Calgary, Alberta, Canada, T2N4N1
      • University of Calgary, Adult CF Clinic
    • Edmonton, Alberta, Canada
      • University of Alberta Hospital
  • Ontario
    • Toronto, Ontario, Canada, T2N4N1
      • St. Michael's Hospital
  • Quebec
    • Montreal, Quebec, Canada, H2W1T7
      • Centre de recherche du CHUM

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• ≥ 6 years of age
• Patient has CF as diagnosed by one of the following:
• Documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test, or
• Two well characterized genetic mutations in the CFTR gene, or
• Abnormal nasal potential difference with accompanying symptoms characteristic of CF
• PA present in expectorated sputum or throat swab culture within 2 months prior to consent
• Patient must be able to provide written informed consent/assent prior to any study related procedure; parent/guardian must be able to give written informed consent as necessary prior to any study related procedure
• At high risk for disease progression as defined by one of the following patient populations:
• FEV1 ≤ 50 % predicted at the time of consent OR
• Completed participation in CP-AI-006 (through Visit 20). Patients who withdraw from CP-AI-006 prior to completing all courses of AZLI and all study visits will not be eligible for this protocol.

Exclusion Criteria:

• Patients with any serious or active medical or psychiatric illness that, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol or dosing requirements
• Patients with hypersensitivity to any of the components of the drug product
• Currently enrolled in another clinical trial
• Pregnant or lactating females

Study Plan

How is the study designed?

Collaborators and Investigators

• Sponsor: Gilead Sciences

Study record dates

Study Registration Dates

• First Submitted: October 2, 2009
• First Submitted That Met QC Criteria: October 5, 2009
• First Posted (Estimate): October 6, 2009

Study Record Updates

• Last Update Posted (Estimate): December 13, 2012
• Last Update Submitted That Met QC Criteria: December 12, 2012
• Last Verified: October 1, 2012

More Information

Terms related to this study

• Keywords: Cystic fibrosis; Expanded access; Pseudomonas aeruginosa; CF; Aztreonam lysine; AZLI; EAP
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Infections; Respiratory Tract Diseases; Lung Diseases; Infant, Newborn, Diseases; Genetic Diseases, Inborn; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Pancreatic Diseases; Fibrosis; Cystic Fibrosis; Pseudomonas Infections; Anti-Infective Agents; Anti-Bacterial Agents; Aztreonam
• Other Study ID Numbers: EA-US-205-0122